The world's most advanced genetic tests

EMAS MED offers a ground-breaking service for the implementation of advanced genetic tests for cancer patients, having the largest possible range of tests. We collaborate with leading laboratories worldwide, with all hospitals in Israel and with the oncology community.

We offer the following genetic tests:

  • Tests to tailor treatment on the basis of a solid biopsy
  • Tests to adjust treatment on the basis of a blood test (liquid biopsy)
  • Second opinion for pathological diagnosis
  • Tests to detect the hereditary component of cancer
  • Evaluation of the benefits of hormone therapy in the treatment of breast cancer
  • Advanced analysis of immune system profiling
  • and more…

Our partners

Medicine tailored to the individual patient's needs

Patient-specific medicine is an approach that has been evolving in recent years. In order to treat cancer effectively, therapy must be tailored to the specific characteristics of each patient. This approach is called “Personalised Medicine”.

Cancer is, among other things, the result of changes in the genome (alterations in DNA), which are responsible for the formation and development of the disease. By determining a unique molecular profile for each patient, abnormalities in the function of genes and proteins that are responsible for the cancer process can be identified. The information obtained from the tests can help the doctor tailor treatment individually for the patient, taking into account the unique genetic characteristics of the tumour. In addition, these tests make it possible to rule out therapies that the tumour might be expected to respond to.

In simple terms, imagine two patients diagnosed with the same type of cancer, in the same location and of the same size. Although they will receive the same treatment, in many cases one will respond positively to treatment, while the other will not respond at all and the disease will progress. Why? Because every patient is different, and every tumour is different!

Molecular profile diagnosis is the most groundbreaking development of the last decade in the field of cancer diagnosis. Unlike imaging technologies such as X-ray, MRI, PET-CT, which examine the tumour as a collection of cells, a kind of ‘black box’, patient-specific medicine goes one step further, inside the cells, looking for the small molecules that are responsible for the tumour process, or, as they have been called, genes and proteins.

This diagnosis makes it possible to differentiate between two patients whose disease appears to be identical, since the differences, as mentioned earlier, are found in the same genetic mutations and protein expression.

Therefore, the determination of the molecular profile makes it possible to predict, for each patient individually, which therapies will be suitable for him or her, and to avoid unnecessary therapies that will have no benefit.


4 things to know about Signatera:

  1. The world’s first test that detects residual disease in the blood after surgery.
  2. Signatera is approved by Medicare, the national health insurer in the US.
  3. Based on the Signatera test, decisions can be made about the need for follow-up treatment after surgery, monitoring the response to current treatment and giving advance warning of a return of disease.
  4. The test is much more sensitive than any imaging test, such as PET-CT or MRI, and can warn months in advance of disease recurrence.

Need for Signater testing:

  • Currently, imaging studies such as PET-CT are the main tools for tracking residual and return of disease after surgery. Imaging studies are only able to detect tumours when they are more than a few millimetres in diameter, and are not sensitive enough to detect small residual disease, which often remains after surgery and leads to disease return.
  • This is where the Signatera test comes in, which is 10 times more sensitive than PET-CT. This test is designed to detect tumour DNA that has been released from the tumour into the blood – called circulating tumour DNA or ctDNA. Because ctDNA survives for only a few hours in the blood, its presence informs us of the status of the tumour, reflecting the state of the disease at the time the sample was taken.
  • The sensitivity of the test is due to its unique way of performing the test – the test involves full sequencing of all 23,000 genes in the patient’s tumour and blood, and then selects 16 genes that are tested individually for each patient to monitor in the blood. When 2 of these 16 genes are detected in the patient’s blood, the test is considered positive. A number of studies on different types of cancer have shown that when the test is positive, the return of the disease is certain, and in such a situation it is highly recommended to undertake follow-up treatment after surgery, such as chemotherapy or immune therapy.
  • Signatera is supported by numerous prospective studies in leading scientific journals in various cancers such as colorectal cancer, breast cancer, bladder cancer, lung cancer, etc., and is covered by Medicare for various indications.

Technical details of the study:

  • Study name: Signatera
  • Laboratory performing the study: Natera, USA
  • Test includes: full genome sequencing of all 23,000 genes in the patient’s tumour and blood, construction of an assay consisting of 16 personalised mutations for each patient, detection of 16 selected mutations in blood with very high sensitivity (sequencing depth of 100,000x)
  • Test material: blood + biopsy
  • Performance time: 5 weeks

For further information and consultation, we are happy to help by telephone or via the contact form.


This test enables you to end long-term hormone treatment and avoid side effects!

Thanks to an innovative test, we will be able to individually and accurately determine whether you respond to long-term hormone treatment after 5 years.

The test saves more than 60% of women treated for breast cancer from long-term hormone treatment and its accompanying side effects.

The test increases the subjects’ confidence in deciding whether or not to continue hormone treatment.

CARIS study of ovarian cancer and FOLR1 staining - for women

The US-based Caris Life Sciences assay is the most comprehensive genomic assay for personalised cancer treatment matching, including full genome sequencing of the entire genome – approximately 23,000 genes (whole exome sequencing), at both the DNA and RNA levels.

Caris is the only company sequencing both DNA and RNA, and additionally performing immunohistochemical staining to detect the presence of the FOLR1 receptor – this staining is essential for matching a breakthrough drug that was recently approved for ovarian cancer patients and was even submitted to the health benefit basket this year.

The staining is carried out according to the Companion Diagnostics protocol – that is, according to the protocol approved to obtain the drug, so positive staining of the FOLR1 receptor in the Caris trial offers the chance of receiving a breakthrough therapy for the disease. Approximately 30 per cent of ovarian cancer patients will be positive for FOLR1 staining, which adds a unique dimension to the trial and significantly increases the chances of finding a personalised therapy in the Caris trial.

4KSCORE blood test - for men

This is a precise blood test used to rule out aggressive prostate cancer. The 4Kscore test is much more accurate than the PSA test.

  • The 4Kscore test allows up to 40% of subjects to avoid a prostate biopsy when it is not necessary.
  • Significant financial savings from avoiding unnecessary procedures.
  • The results of the study are presented in a comprehensive report that assesses the risk of aggressive prostate cancer and provides information on risk over the next 20 years.
  • In most cases, prostate cancer develops slowly and is not life-threatening. The 4Kscore test allows precise treatment adjustment and prevents unnecessary interventions.
  • The 4Kscore test is recommended by international guidelines (NCCN, EAU) for the diagnosis of prostate cancer.


The DECIPHER test answers 4 questions:

  1. I have been diagnosed with Gleason 6 prostate cancer – should I treat the cancer or settle for observation?
  2. I have been diagnosed with intermediate grade prostate cancer – should I add hormone therapy to radiotherapy?
  3. I have undergone a prostatectomy – should I receive radiotherapy?
  4. I have undergone a prostatectomy and my PSA has increased – should I receive hormone therapy?

What is the DECIPHER test?

The Decipher genetic test actually answers one basic question – whether the tumour is ‘quiescent’ and has a low level of malignancy, requiring minimal treatment or observation, or whether it is a ‘wolf in sheep’s clothing’, with the potential to develop into an aggressive and life-threatening tumour. By focusing on the genes that regulate tumour growth, the malignancy of the tumour can be accurately tracked and the development of the disease can be predicted, for up to 10 years.

How does the test work?

The test is performed on a biopsy or, in the case of a prostatectomy, on material from the prostatectomy itself. The genetic material from the sample, the RNA, is analysed by full sequencing using the Whole Transcriptome RNA method, and the activity levels of various genes are summarised by a unique algorithm that accurately assesses the degree of malignancy of the sample. Once the process is complete, a report is sent to the treating physician, describing the degree of malignancy of the tumour over a 10-year period and the recommended therapy.

Why perform this test instead of settling for a simple pathological examination?

It is worth remembering that without a genetic test – a test that verifies which genes have been attached to the growth of the tumour – the doctor is mainly left with a pathological examination, which is known for its low and subjective accuracy, depending mainly on the eyes of the pathologist who assesses the sample. The Gleason index, which pathologists use to assess the malignancy of a specimen, can vary between two pathology tests, and often the test gives an assessment that distorts the malignancy of the tumour.

Is the test covered by health insurers and insurance companies?
Significant reimbursements for the test can be obtained from health insurers and private insurance companies, depending on each test subject’s insurance type. Progenetics offers insurance consultations and will be happy to help and advise on this issue.

Technical details of the test:

  • Name of the test: Decipher
  • Performing laboratory: Decipher Biosciences, USA
  • Test includes: full RNA whole-exome sequencing to assess tumour malignancy
  • Test material: biopsy, prostatectomy
  • Performance time: 2-3 weeks

For additional information and consultations, we are happy to help by phone or via the contact form.


CARIS is the most comprehensive and precise tool for customising advanced cancer therapies.

  • Most comprehensive analysis: sequencing of approximately 23,000 genes at the DNA level, examination of the expression of 23,000 genes at the RNA level and protein staining as appropriate.
  • Most precise analysis: sequencing depth of approximately 1,000x.
  • Highest success rate in the industry: operating even under conditions of limited biopsy material.
  • Experienced and established company: the US-based Caris Life Sciences is a leader in the field and has nearly 1,000 employees in the US and Europe. It has extensive experience and a database covering hundreds of thousands of patients.

Pioneering a new era in personalised cancer treatment

Caris Life Sciences

Caris Life Sciences is a leading innovator in molecular science, focused on fulfilling the promise of precision medicine through quality and innovation. As the first to offer comprehensive molecular profiling in oncology, Caris is an industry leader with more than 150,000 tumours profiled.

Cancer profiling

Caris Molecular Intelligence is the first and most experienced comprehensive cancer profiling service designed to enable the delivery of precision medicine. Our comprehensive approach to cancer profiling assesses DNA, RNA and proteins to reveal the molecular blueprint to guide more precise and personalised treatment decisions. The Caris Molecular Intelligence report is generated for each patient and can help the clinician personalise cancer-specific therapies.

Considering tumour profiling

Biomarker analysis can help you and your doctor identify potential treatment options for your disease. Your doctor may consider molecular profiling if:

  • your cancer has metastasised or recurred;
  • you are struggling with an aggressive or rare cancer;
  • your doctor is using multiple treatment options; or
  • you have run out of standard treatment options.

Tumour profiling from Caris Life ScienceĀ® is only available for patients with solid tumours and must be ordered by a doctor.

How does Caris Molecular Intelligence profiling work?

Caris Molecular Intelligence uses multiple tumour profiling technologies to decode cancer and better understand the biology driving tumour growth. Biomarker results or a molecular blueprint from a tissue sample are then matched to anti-cancer therapies associated with benefit or non-benefit, as well as clinical trials for a given cancer. Caris Molecular Intelligence matches biomarkers to therapies using a comprehensive review of the strongest and most relevant clinical and scientific studies related to cancer. This information, or Molecular Intelligence, can be used by the clinician to personalise treatment, which can lead to a better response to treatment.

Does the report tell doctors how to treat cancer?

The report is a tool that provides a molecular blueprint to help the doctor assess and make more precise and individualised treatment decisions. The patient and doctor will establish a treatment plan that is based on a number of factors, including the report, availability of cancer drugs, medical history and other clinical factors.

Does the report include information on clinical trials?

Yes, through the Clinical Trials ConnectorTM, the report identifies clinical trial opportunities that are currently recruiting patients based on unique biomarkers in the tumour. Your doctor will determine if any of these trials may be suitable for you.

What type of tissue sample is needed to profile my tumour?

The Caris Molecular IntelligenceĀ® test is performed on solid tumour tissue that is routinely obtained during surgical removal of the tumour or from a biopsy sample. As tumour biomarkers can change over time and during treatment, the clinician may wish to obtain a more up-to-date tumour sample.

When will my results be ready?

Once our laboratory receives the sample and the required documentation, the process usually takes 14-21 days. The report will be delivered directly to your doctor for review.

How does my doctor receive my results?

The MI Profile report containing the results is sent to your doctor via a secure email.


Caris Molecular IntelligenceĀ® uses multiple tumour profiling technologies to decode cancer and better understand the biology driving tumour growth. Biomarker results or a molecular blueprint from a tissue sample are then matched to anti-cancer drugs associated with benefit or non-benefit, as well as clinical trials for a particular cancer.

How to perform the test - step by step

The new era of medicine.

State-of-the-art cancer profiling methods in the world

The time for smart cancer treatment has come

We check up to 22500 genes!

The Caris Molecular IntelligenceĀ® test can only be ordered by physicians. If you would like to explore the possibility of ordering tumor profiling from Caris Life SciencesĀ®, please consult your oncologist or us.